Last reviewed · How we verify
NCT06129604
Pilot Window of Opportunity Trial (POET)
Phase 2 trial testing TPST-1495 in Colorectal Carcinoma (CRC) in 10 participants. Participants enrolled and being followed up; not accepting new ones.
22 August 2025
Quick facts
| Lead sponsor | University of Oklahoma |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 April 2024 |
| Primary completion | 22 August 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TPST-1495 — full drug profile →
Conditions studied
- Colorectal Carcinoma (CRC) — all drugs for Colorectal Carcinoma (CRC) →
- Endometrial Carcinoma (EC) — all drugs for Endometrial Carcinoma (EC) →
Sponsor
University of Oklahoma
Who can join
18 and older, any sex, with Colorectal Carcinoma (CRC) or Endometrial Carcinoma (EC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed clinical trial with TPST-1495 can help people with two types of cancer, Endometrial Cancer (EC) and Colorectal Carcinoma (CRC), who need surgery. The investigator plans to evaluate how well TPST-1495 works against these cancers by checking blood samples and tumor tissues taken before and after the treatment to see if it is an effective treatment option to help the immune system fight against cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.
Sheremeta CL, Yarlagadda S, Smythe ML, Noakes PG. · · 2024 · cited 8× · PMID 39177131 · DOI 10.2174/0113894501323980240815113851 -
Recent updates in mammalian oxylipin biochemistry.
O'Donnell VB. · · 2025 · cited 1× · PMID 40876591 · DOI 10.1016/j.jbc.2025.110629 -
Plasticity of myeloid-derived suppressor cells in cancer and cancer therapy.
Lv J, Zhong X, Wang L, Fan W. · · 2025 · cited 1× · PMID 40612857 · DOI 10.32604/or.2025.060063
Verify or expand the search:
- PubMed search for NCT06129604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Carcinoma (CRC)
Currently open trials in the same condition.
- NCT07422974 — Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer · recruiting
Other University of Oklahoma trials
Trials by the same sponsor.
- NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
- NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
- NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06129604 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06129604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing